09:51 AM EST, 12/31/2024 (MT Newswires) -- Amgen's ( AMGN ) tarlatamab has been approved by the UK's Medicines and Healthcare products Regulatory Agency to treat adults with small cell lung cancer that has spread throughout the lungs and/or to other parts of the body, the regulator said Tuesday.

The drug can only be prescribed to people that were previously treated with two other types of treatments and if those treatments didn't work or are no longer working, the regulator said.

Amgen ( AMGN ) shares were 0.4% higher in recent trading.

Price: 260.40, Change: +1.09, Percent Change: +0.42